Drug Name |
Selumetinib
|
||
Synonyms |
Selumetinib; AZD-6244; ARRY142886; AZD6244; ARRY142886; AZD 6244; AZD-6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U
|
||
Drug Type |
Small molecular drug
|
||
Indications |
Non-small-cell lung cancer [ICD-11: 2C25.Y]
|
Phase 2
|
|
Melanoma [ICD-11: 2C30]
|
Phase 3
|
||
Thyroid cancer [ICD-11: 2D10]
|
Phase 3
|
||
Solid tumour/cancer [ICD-11: 2A00-2F9Z]
|
Investigative
|
||
Company |
AstraZeneca
|
||
Summary |
Selumetinib is a MEK 1/2 inhibitor used in pediatric patients to treat neurofibromatosis type 1 (NF1) accompanied by symptomatic, inoperable plexiform neurofibromas (PN).
|
||
Target |
MAPK/ERK kinase kinase (MAP3K)
Mechanism of Action: Modulator
|
T23003 | |
ERK activator kinase 2 (MEK2)
Mechanism of Action: Inhibitor
|
T89055 | ||
ERK activator kinase 1 (MEK1)
Mechanism of Action: Inhibitor
|
T35940 |
![]() |
Formula |
C17H15BrClFN4O3
|
Canonical SMILES |
CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO
|
|
InChI |
1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
|
|
InChIKey |
CYOHGALHFOKKQC-UHFFFAOYSA-N
|
|
CAS Number | CAS 606143-52-6 | |
TTD ID | D0T5DP | |
DrugBank ID | DB11689 | |
PubChem Compound ID | 10127622 | |
PubChem Substance ID |
15117183
,
22530930
,
39966063
,
53837732
,
57374224
,
76853338
,
91146061
,
99431772
,
123051124
,
124490406
,
124756930
,
124899407
,
124963590
,
125163737
,
125329930
,
125569760
,
126580498
,
126644899
,
126665950
,
126737693
,
131465101
,
131477688
,
135262198
,
135344948
,
135602608
,
135685252
,
135685253
,
135685272
,
135686160
,
135686161
,
135686182
,
135686183
,
135727389
,
136368075
,
136920282
,
136959521
,
137220034
,
139721905
,
143499011
,
144115657
,
144206913
,
152043674
,
152235945
,
152258818
,
152344235
,
160647668
,
160813024
,
162011399
,
162037381
,
162200063
|
|
ChEBI ID | CHEBI:90227 | |
ADReCS Drug ID | NA |
ID | Name | Dose | Type | Drug Brand Name | Drug Dose | Drug Dosage Form | Experimental Species | Individuals Number | Test Sample | Ingredient | Effect | Relationship Classification | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ID | Name | Dose | Type | Drug Brand Name | Drug Dose | Drug Dosage Form | Experimental Species | Individuals Number | Test Sample | Ingredient | Effect | Relationship classification |